30 closest matches · ranked by relevance
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Heart Disease
Primary: Number of Patients With Atrial Arrhythmia — 121; 134 Participants — p=0.34
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
Non-small Cell Lung Cancer
Primary: Number of Participants With Adverse Drug Reactions — 1858; 518 Participants
HIV-1 Infection
Primary: Number of Participants Who Reported Unlisted Adverse Drug Reaction. — 0 participants
Plaque Psoriasis
Primary: Hypothalamic-Pituitary-Adrenal (HPA) Axis Response — 19; 6 Participants
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Acromegaly
Primary: Number of Participants With Treatment-Related Adverse Events — 89; 20 Participants
Acute Pain · Dysmenorrhea
Primary: Percentage of Patients With an Incidence of Adverse Event (AE) Associated to Potential Liver Damage During the Clinical Evaluation of Patients — 0.0 Percentage of Patients
Schizophrenia
Primary: Assessment of Negative Symptoms and Neuroleptic Induced Deficit Syndromes by Objective Rating Scales — -1.30; -0.28; -0.66; -0.70 units on a scale
Healthy Volunteers
Primary: Maximum Level of Sedation for Lorazepam 1 mg IM + ADASUVE 10 mg — 12.3 units on a scale
Small for Gestational Age
Primary: Number of Participants With Treatment Related Adverse Events. — 44 participants
Non-tuberculous Mycobacterial Diseases · Tuberculosis · Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
Primary: Number of Patients With Adverse Drug Reactions in This Surveillance — 16; 7 Participants
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Treatment-Related Adverse Events — 450 Participants
Pulmonary Hypertension
Primary: Number of Participants With Treatment-Related Adverse Events — 448; 101 Participants
CCR5-tropic HIV-1 Infection
Primary: Percentage of Participants With Adverse Drug Reactions (ADRs) — 23.53 percentage of participants
Epilepsies, Partial
Primary: Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert — 27 participants
Tuberculosis · Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
Primary: Number of Participants With Treatment-Related Adverse Events — 387; 113 Participants
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
Hemophilia A
Primary: Number of Participants Who Discontinued the Use of Study Drug — 10; 5 Participants
COPD · Sepsis · Shock
Primary: Heart Rate in Beats Per Minute — -0.16; 1.40 bpm — p=0.01
Essential Hypertension
Primary: Number of Participants Experiencing AEs or ADRs — 184; 59 Participants
Melanoma
Primary: Number of Participants Who Completed Treatment — 120 Participants
Eosinophilic Esophagitis (EoE)
Primary: Part A (SAD): Number of Treatment Emergent Adverse Events (TEAEs) by Participant — 1; 0; 1; 2 Participants
Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, Perennial · Urticaria
Primary: Number of Adverse Events Reported By Category After 14 Days of Treatment — 26; 21; 4; 1 Adverse Events
Rheumatoid Arthritis
Primary: Incidence of Adverse Drug Reactions (ADRs) — 33.3 Percentage of participants
Hypertension
Primary: Unexpected Adverse Events — 0.58 Percentage of patients
Non Small Cell Lung Cancer · Malignant Pleural Mesothelioma
Primary: Safety Assessment Including Treatment-related Adverse Events (Number of Participants Who Experienced at Least One Adverse Event (AE) or One Serious Adverse Event (SAE))…
Hymenoptera Venom Allergy · Antihypertensive Treatment
Primary: Frequency of Side Effects (=Systemic Reaction, SR) During Venom Immunotherapy (VIT) — 19; 74 Participants — p=0.25